Exelixis Inc
EXEL36.220USD
-0.635-1.72%
Cierre 07/31, 16:00（ET）Cotizaciones retrasadas 15 min
9.78BCap. mercado
15.20P/E TTM
Más Datos de Exelixis Inc Compañía
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Información de la empresa
Símbolo de cotizaciónEXEL
Nombre de la empresaExelixis Inc
Fecha de salida a bolsaApr 11, 2000
Fundada en1994
Director ejecutivoDr. Michael M. Morrissey, Ph.D.
Número de empleados1147
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 11
Dirección1851 Harbor Bay Parkway
CiudadALAMEDA
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94502
Teléfono16508377000
Sitio Webhttps://www.exelixis.com/
Símbolo de cotizaciónEXEL
Fecha de salida a bolsaApr 11, 2000
Fundada en1994
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.27M
-4.42%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.27M
+0.78%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
258.52K
-25.63%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
159.99K
+6.53%
Dr. Amy C. Peterson, M.D.
Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
151.08K
-21.38%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
81.98K
+13.60%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
10.57K
+1285.98%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.27M
-4.42%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.27M
+0.78%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
258.52K
-25.63%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
CABOMETYX
510.87M
91.97%
License revenues
42.48M
7.65%
COMETRIQ
2.41M
0.43%
Collaboration services revenues
-316.00K
-0.06%
Por regiónUSD
Nombre
Ganancia
Proporción
U.S
517.18M
93.11%
Europe
32.71M
5.89%
Japan
5.56M
1.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
CABOMETYX
510.87M
91.97%
License revenues
42.48M
7.65%
COMETRIQ
2.41M
0.43%
Collaboration services revenues
-316.00K
-0.06%
Estadísticas de accionistas
Actualizado: jue., 22 de may
Actualizado: jue., 22 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.63%
BlackRock Institutional Trust Company, N.A.
9.84%
Farallon Capital Management, L.L.C.
6.92%
Renaissance Technologies LLC
5.51%
State Street Global Advisors (US)
4.38%
Other
62.72%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.63%
BlackRock Institutional Trust Company, N.A.
9.84%
Farallon Capital Management, L.L.C.
6.92%
Renaissance Technologies LLC
5.51%
State Street Global Advisors (US)
4.38%
Other
62.72%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
44.30%
Investment Advisor/Hedge Fund
26.92%
Hedge Fund
15.92%
Pension Fund
3.14%
Individual Investor
2.20%
Research Firm
1.98%
Sovereign Wealth Fund
1.28%
Bank and Trust
0.50%
Family Office
0.16%
Other
3.60%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
1059
262.65M
97.57%
-13.60M
2025Q1
1059
268.29M
98.20%
-10.58M
2024Q4
992
262.76M
93.66%
-11.36M
2024Q3
924
259.58M
90.96%
-10.18M
2024Q2
908
255.61M
87.75%
-22.29M
2024Q1
905
264.69M
87.26%
-20.82M
2023Q4
882
270.85M
87.07%
-16.64M
2023Q3
847
278.02M
87.32%
-18.15M
2023Q2
833
285.95M
87.85%
-21.34M
2023Q1
841
294.75M
90.97%
-14.08M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
28.61M
10.49%
-757.26K
-2.58%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
26.49M
9.71%
-219.09K
-0.82%
Mar 31, 2025
Farallon Capital Management, L.L.C.
18.64M
6.83%
-3.90M
-17.30%
May 16, 2025
Renaissance Technologies LLC
14.82M
5.44%
-471.60K
-3.08%
Mar 31, 2025
State Street Global Advisors (US)
11.79M
4.32%
+377.67K
+3.31%
Mar 31, 2025
LSV Asset Management
8.16M
2.99%
-8.51K
-0.10%
Mar 31, 2025
Fuller & Thaler Asset Management Inc.
7.80M
2.86%
+164.13K
+2.15%
Mar 31, 2025
Geode Capital Management, L.L.C.
7.42M
2.72%
+2.26M
+43.80%
Mar 31, 2025
AQR Capital Management, LLC
6.89M
2.53%
+2.93M
+73.78%
Mar 31, 2025
Invesco Capital Management LLC
4.61M
1.69%
+1.43M
+44.74%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
Adaptiv Select ETF
149.65%
Invesco Dorsey Wright Healthcare Momentum ETF
4.87%
Tema Oncology ETF
4.38%
iShares Genomics Immunology and Healthcare ETF
4.11%
First Trust NYSE Arca Biotechnology Index Fund
3.83%
Invesco Biotechnology & Genome ETF
3.38%
Burney US Factor Rotation ETF
2.79%
SPDR S&P Biotech ETF
2.68%
First Trust Health Care Alphadex Fund
2.65%
ERShares Entrepreneurs ETF
2.49%
Ver más
Adaptiv Select ETF
Proporción149.65%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción4.87%
Tema Oncology ETF
Proporción4.38%
iShares Genomics Immunology and Healthcare ETF
Proporción4.11%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.83%
Invesco Biotechnology & Genome ETF
Proporción3.38%
Burney US Factor Rotation ETF
Proporción2.79%
SPDR S&P Biotech ETF
Proporción2.68%
First Trust Health Care Alphadex Fund
Proporción2.65%
ERShares Entrepreneurs ETF
Proporción2.49%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
